We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips Expands Women's Health Ultrasound Portfolio With New Transducer
Read MoreHide Full Article
Key Takeaways
Philips launches the eV14-2v transducer for gynecology and early obstetrics imaging.
PHG's eV14-2v offers greater penetration, higher resolution, a wider view and a lighter design.
Philips integrates eV14-2v with Collaboration Live to enable real-time remote ultrasound consultations.
Koninklijke Philips (PHG - Free Report) has expanded its women's health ultrasound portfolio with the launch of the eV14-2v transvaginal transducer, designed for gynecology and early obstetrics imaging. The FDA 510(k)-cleared and CE-marked solution will be showcased at the ISUOG 2026 World Congress, reinforcing the company's focus on advancing ultrasound innovation.
From an investor's perspective, the launch strengthens Philips' position in the premium ultrasound market by broadening its women's health offerings with a solution aimed at improving workflow efficiency and clinical versatility. The addition complements the company's AI-enabled and connected imaging ecosystem, supporting its long-term strategy to drive adoption of higher-value imaging technologies across healthcare providers.
Likely Trend of PHG Stock Following the News
Following the announcement, shares of PHG traded flat on Friday. Year to date, shares of the company have lost 4.4% compared with the industry’s 17.4% decline. However, the S&P 500 has risen 12.2% in the same timeframe.
The eV14-2v launch is likely to strengthen Philips' long-term ultrasound franchise by expanding its differentiated women's health portfolio with a premium imaging solution that reduces workflow disruptions and enhances diagnostic capabilities across gynecology and early obstetrics. Its compatibility with Philips' broader ultrasound ecosystem, including Collaboration Live and flagship imaging platforms, can encourage platform stickiness, support replacement demand and drive higher-value equipment and accessory sales, reinforcing the company's competitive position in the growing women's health imaging market.
PHG currently has a market capitalization of $25.45 billion.
Image Source: Zacks Investment Research
More on the News
The eV14-2v was developed to address a common challenge in gynecology and early obstetrics imaging, where clinicians often need to switch between transducers to balance penetration and image resolution, disrupting workflow and extending exam times. The new transducer combines enhanced penetration, improved image quality and a wider field of view in a single lightweight device. Compared with Philips' previous-generation 3D9-3v transducer, it delivers 41.7% greater penetration, 10% higher 2D resolution, a 15.8% wider field of view and a 22% lighter design, supporting both routine and more complex women's health examinations.
Built specifically for obstetrics and gynecology, the eV14-2v incorporates Philips' PureWave crystal technology and an ergonomic design that enhances clinician comfort during extended examinations. The improved imaging capabilities provide detailed visualization for evaluating infertility, pelvic pain, endometriosis and uterine fibroids. The system also supports early fetal assessment by enabling clinicians to distinguish fetal cardiac chambers as early as 13 weeks of pregnancy, when the heart is approximately the size of a corn kernel, strengthening its utility across a wide range of women's healthcare applications.
Philips has also integrated the eV14-2v with its Collaboration Live platform, enabling real-time remote consultations during ultrasound examinations. The feature allows specialists to review live imaging, guide sonographers during scans and collaborate with care teams without requiring patients to travel, potentially expanding access to specialty care in underserved communities.
Industry Prospects Favoring the Market
According to the data provided by Grand View Research, the global obstetrics & gynecology ultrasound devices market size was estimated at $2.13 billion in 2024 and is projected to reach $2.84 billion by 2030, expanding at a CAGR of 4.94% from 2025 to 2030.
Growth in the forecast period can be attributed to the increasing prevalence of gynecological and obstetric disorders, such as uterine fibroids, ovarian cysts and high-risk pregnancies, creating a demand for early and accurate diagnoses.
Other News
Recently, PHG announced that its EU-backed COMBINE-CT project has advanced from technology development to clinical validation, marking a key milestone in its AI-enabled cardiac imaging strategy. The four-year initiative, launched in 2023, has begun five multicenter clinical studies to evaluate an integrated CT-based care pathway for coronary artery disease, using AI-powered CT and Spectral CT imaging to support diagnosis, treatment planning, procedure guidance and follow-up care.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Philips Expands Women's Health Ultrasound Portfolio With New Transducer
Key Takeaways
Koninklijke Philips (PHG - Free Report) has expanded its women's health ultrasound portfolio with the launch of the eV14-2v transvaginal transducer, designed for gynecology and early obstetrics imaging. The FDA 510(k)-cleared and CE-marked solution will be showcased at the ISUOG 2026 World Congress, reinforcing the company's focus on advancing ultrasound innovation.
From an investor's perspective, the launch strengthens Philips' position in the premium ultrasound market by broadening its women's health offerings with a solution aimed at improving workflow efficiency and clinical versatility. The addition complements the company's AI-enabled and connected imaging ecosystem, supporting its long-term strategy to drive adoption of higher-value imaging technologies across healthcare providers.
Likely Trend of PHG Stock Following the News
Following the announcement, shares of PHG traded flat on Friday. Year to date, shares of the company have lost 4.4% compared with the industry’s 17.4% decline. However, the S&P 500 has risen 12.2% in the same timeframe.
The eV14-2v launch is likely to strengthen Philips' long-term ultrasound franchise by expanding its differentiated women's health portfolio with a premium imaging solution that reduces workflow disruptions and enhances diagnostic capabilities across gynecology and early obstetrics. Its compatibility with Philips' broader ultrasound ecosystem, including Collaboration Live and flagship imaging platforms, can encourage platform stickiness, support replacement demand and drive higher-value equipment and accessory sales, reinforcing the company's competitive position in the growing women's health imaging market.
PHG currently has a market capitalization of $25.45 billion.
Image Source: Zacks Investment Research
More on the News
The eV14-2v was developed to address a common challenge in gynecology and early obstetrics imaging, where clinicians often need to switch between transducers to balance penetration and image resolution, disrupting workflow and extending exam times. The new transducer combines enhanced penetration, improved image quality and a wider field of view in a single lightweight device. Compared with Philips' previous-generation 3D9-3v transducer, it delivers 41.7% greater penetration, 10% higher 2D resolution, a 15.8% wider field of view and a 22% lighter design, supporting both routine and more complex women's health examinations.
Built specifically for obstetrics and gynecology, the eV14-2v incorporates Philips' PureWave crystal technology and an ergonomic design that enhances clinician comfort during extended examinations. The improved imaging capabilities provide detailed visualization for evaluating infertility, pelvic pain, endometriosis and uterine fibroids. The system also supports early fetal assessment by enabling clinicians to distinguish fetal cardiac chambers as early as 13 weeks of pregnancy, when the heart is approximately the size of a corn kernel, strengthening its utility across a wide range of women's healthcare applications.
Philips has also integrated the eV14-2v with its Collaboration Live platform, enabling real-time remote consultations during ultrasound examinations. The feature allows specialists to review live imaging, guide sonographers during scans and collaborate with care teams without requiring patients to travel, potentially expanding access to specialty care in underserved communities.
Industry Prospects Favoring the Market
According to the data provided by Grand View Research, the global obstetrics & gynecology ultrasound devices market size was estimated at $2.13 billion in 2024 and is projected to reach $2.84 billion by 2030, expanding at a CAGR of 4.94% from 2025 to 2030.
Growth in the forecast period can be attributed to the increasing prevalence of gynecological and obstetric disorders, such as uterine fibroids, ovarian cysts and high-risk pregnancies, creating a demand for early and accurate diagnoses.
Other News
Recently, PHG announced that its EU-backed COMBINE-CT project has advanced from technology development to clinical validation, marking a key milestone in its AI-enabled cardiac imaging strategy. The four-year initiative, launched in 2023, has begun five multicenter clinical studies to evaluate an integrated CT-based care pathway for coronary artery disease, using AI-powered CT and Spectral CT imaging to support diagnosis, treatment planning, procedure guidance and follow-up care.
Koninklijke Philips N.V. Price
Koninklijke Philips N.V. price | Koninklijke Philips N.V. Quote
PHG’s Zacks Rank & Key Picks
Currently, PHG has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.